The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 23, 2019
Filed:
Feb. 27, 2017
Applicant:
Lodoco Clinical Kft., Budapest, HU;
Inventors:
Tibor Bakács, Budapest, HU;
Ralf Kleef, Vienna, AT;
Assignee:
Other;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 31/549 (2006.01); A61K 31/675 (2006.01); C07K 16/30 (2006.01); A61K 38/20 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 31/549 (2013.01); A61K 31/675 (2013.01); A61K 38/2013 (2013.01); A61K 39/0008 (2013.01); A61K 39/00115 (2018.08); A61K 39/3955 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract
A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.